NovoCure (NASDAQ:NVCR) Shares Gap Up – Here’s What Happened

NovoCure Limited (NASDAQ:NVCR) gapped up prior to trading on Thursday . The stock had previously closed at $11.93, but opened at $13.36. NovoCure shares last traded at $14.2460, with a volume of 761,080 shares changing hands.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q1 revenue beat and solid organic growth: Revenue was $174.1M vs. consensus ~$167.8M, up ~12% year‑over‑year — investors are rewarding top‑line strength. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
• Positive Sentiment: Company raised FY‑2026 sales guidance to $690M–$710M, signaling confidence in demand and recurring treatment adoption (guidance sits around analyst estimates). That outlook upgrade is the primary bullish catalyst. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
• Neutral Sentiment: Analyst/commentary pieces are highlighting the stock’s breakout potential and explaining the rally — useful for sentiment/context but not new fundamental data. Two medical stocks skyrocket after demolishing views — and one is about to break out
• Neutral Sentiment: Company released the earnings slide deck and full call/transcript — useful for digging into drivers, regional trends and unit economics (see slides/call for color on adoption and margin plans). NovoCure Q1 slide deck NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
• Negative Sentiment: EPS missed: GAAP loss of ($0.62) vs. consensus (~$0.51) and wider than last year’s ($0.31) — profitability pressures and higher operating costs remain a concern for profit‑focused investors. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Company remains unprofitable with negative net margin and ROE; consensus still expects negative EPS for the year — longer path to consistent profitability increases risk if revenue momentum slows. NovoCure: Q1 Earnings Snapshot

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a report on Tuesday, April 21st. Evercore reiterated an “outperform” rating on shares of NovoCure in a report on Friday. Finally, Wedbush reiterated a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a report on Thursday, April 16th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $26.93.

NovoCure Stock Up 9.3%

The company has a quick ratio of 2.71, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. The stock’s fifty day moving average price is $12.11 and its 200-day moving average price is $12.45. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.62 and a beta of 0.90.

NovoCure (NASDAQ:NVCR) last released its earnings results on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.34%. The firm had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same period in the prior year, the business posted ($0.31) earnings per share. NovoCure’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, sell-side analysts predict that NovoCure Limited will post -1.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Chairman William F. Doyle sold 71,887 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total value of $933,093.26. Following the completion of the transaction, the chairman directly owned 328,397 shares of the company’s stock, valued at approximately $4,262,593.06. This trade represents a 17.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mukund Paravasthu sold 43,246 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $13.77, for a total transaction of $595,497.42. Following the completion of the transaction, the chief operating officer directly owned 72,832 shares of the company’s stock, valued at $1,002,896.64. This represents a 37.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 140,041 shares of company stock valued at $1,860,116 in the last ninety days. 5.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NovoCure

Several hedge funds and other institutional investors have recently made changes to their positions in NVCR. Morgan Stanley grew its stake in shares of NovoCure by 453.4% in the fourth quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after buying an additional 4,153,741 shares in the last quarter. Soleus Capital Management L.P. boosted its position in NovoCure by 25.0% during the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock worth $122,897,000 after purchasing an additional 1,382,888 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in NovoCure by 1,093.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock worth $15,823,000 after purchasing an additional 1,121,192 shares during the period. SG Americas Securities LLC boosted its position in NovoCure by 346.7% during the first quarter. SG Americas Securities LLC now owns 1,245,541 shares of the medical equipment provider’s stock worth $13,576,000 after purchasing an additional 966,735 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in NovoCure during the fourth quarter worth $11,991,000. 84.61% of the stock is owned by institutional investors.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.